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Abstract 
The majority of big data is unstructured and of this majority the largest chunk is text. While 
data mining techniques are well developed and standardized for structured, numerical data, 
the realm of unstructured data is still largely unexplored. The general focus lies on 
“information extraction”, which attempts to retrieve known information from text. The “Holy 
Grail”, however is “knowledge discovery”, where machines are expected to unearth entirely 
new facts and relations that were not previously known by any human expert. Indeed, 
understanding the meaning of text is often considered as one of the main characteristics of 
human intelligence.  
The ultimate goal of semantic artificial intelligence is to devise software that can 
“understand” the meaning of free text, at least in the practical sense of providing new, 
actionable information condensed out of a body of documents.  As a stepping stone on the 
road to this vision I will introduce a totally new approach to drug research, namely that of 
identifying relevant information by employing a self-organizing semantic engine to text mine 
large repositories of biomedical research papers, a technique pioneered by Merck with the 
InfoCodex software. I will describe the methodology and a first successful experiment for the 
discovery of new biomarkers and phenotypes for diabetes and obesity on the basis of PubMed 
abstracts, public clinical trials and Merck internal documents. The reported approach shows 
much promise and has potential to impact fundamentally pharmaceutical research as a way to 
shorten time-to-market of novel drugs, and for early recognition of dead ends. 
 
 
Big data: challenges and opportunities 
Rivers of ink have been poured to describe the data deluge that is increasingly defining our 
information society. While I do not want to dwell too long on something we all are 
experiencing daily, the concrete numbers are nonetheless staggering [1]. Here are some 
examples: 
Ø In 2007 more data have been accumulated than can fit on all of the world’s available 
storage. 
Ø In 2011 this number has reached the limit of twice as much data as can be stored on 
all of the world’s storage i.e. 1200 billions gigabytes. 
Ø The CMS detector at the CERN LHC accelerator accumulates data at a rate of 320 
terabits/s, which makes it necessary to filter data by hardware “on the way” to reduce 
to flux to “only” 800 Gbp/s. 
Ø Wal-Mart feeds 1 million customer transaction/hour into its databases . 
Ø Internet: 1 trillion unique URLs have been indexed by Google. 
Ø 12.8 million blogs have been recently recorded, not counting Asia, this number is 
growing exponentially. 
Ø The number of emails sent per day in 2010 was 294 billion. 
Ø In 2008 Google received 85’000 CVs for the one single post of software engineer. 
These numbers pose huge challenges on both hardware and software. However, as is usually 
the case, challenges and opportunities go hand in hand. In this paper I shall concentrate on the 
opportunity side of the equation.  
Data come in two flavours: structured and unstructured. Structured data consist typically of 
numbers organized in structures, like tables, charts or series. Unstructured data are essentially 
everything else and make up around 85% [2] of the data deluge. Of these, the vast majority is 
text, the rest being pictures, video and sound tracks. In this paper I shall concentrate on text 
data.  
There is only one thing you can do with numbers: analyze them to discover relationships and 
dependencies. The basic method to do this is statistical analysis, whose development was 
initiated in the 17th century with the works of  Pascal, Fermat, de Moivre, Laplace and 
Legendre and got new impetus in the late 19th and early 20th century from Sir Francis Galton 
and Karl Pearson [3]. Today, statistical analysis if often complemented by methods from 
computer science and information theory to detect unsuspected patterns and anomalies in 
very large databases, a technique that goes under the name of data mining [4].  
While statistical analysis and data mining are complex and require trained specialists, 
unstructured data pose even bigger challenges. First of all there are two things you can do 
with text: teach machines to understand what the text in a given document means and have 
them “read” large quantities of text documents to uncover hidden, previously unnoticed 
correlations pointing to entire new knowledge. Both are very difficult but the latter is far 
more difficult than the former.  
 
 
Information extraction and knowledge discovery in research papers  
 
Understanding written language is a key component of human intelligence. Correspondingly, 
doing something useful with large quantities of text documents that are out of reach for 
human analysis requires, unavoidably some form of artificial intelligence [5]. This is why 
handling unstructured data is harder than analyzing their numerical counterpart, for which 
well-defined and developed mathematical methods are readily available. Indeed, there is as 
yet no standard approach to text mining, the unstructured counterpart to data mining.  
There are several approaches to teach a machine to comprehend text [6-8]. The vast bulk of 
research and applications focuses on natural language processing (NLP) techniques for 
information extraction (IE). Information extraction aims to identify mentions of named 
entities (e.g. “genes” in life science applications) and relationships between these entities (as 
in “is a” or “is caused by”). Entities and their relations are often called “triples” and databases 
of identified triples “triple stores”. Such triple stores are the basis of the Web 3.0 vision, in 
which machines will be able to automatically recognize the meaning of online documents 
and, correspondingly, interact intelligently with human end users. IE techniques are also the 
main tool used to curate domain-specific terminologies and ontologies extracted from large 
document corpora.  
Information extraction, however, is not thought for discovery. By its very design, it is limited 
to identifying semantic relationships that are explicitly lexicalized in a document: by 
definition these relations are known to the human expert who formulated them. The “Holy 
Grail” [9] of the text mining, instead is knowledge discovery from large corpora of text. Here 
one expects machines to generate novel hypotheses by uncovering previously unnoticed 
correlations from information distributed over very large pools of documents. These 
hypotheses must then be tested experimentally. Knowledge discovery is about unearthing 
implicit information versus the explicit relations recovered by information extraction. The 
present paper is about machine knowledge discovery in the biomedical and 
pharmacogenomics literature.  
 
21st century challenges for pharmaceutical research 
Pharmaceutical research is undergoing a profound change. The deluge of molecular data and 
the advent of computational approaches to analyze them have revolutionized the traditional 
process of discovering drugs by happenstance in natural products or synthetizing and 
screening large libraries of small molecule compounds. Today, computational methods 
permeate so many aspects of pharmaceutical research that one can say that drugs are 
“designed” rather than “discovered” [10,11]. 
Molecular data found in genomics and proteomics databases are typically structured data. As 
in other domains, the bulk of the computational effort in the pharmaceutical industry goes 
into crunching structured molecular data. There is, however another, even larger source of 
valuable information that can potentially be tapped for discoveries: repositories of research 
documents. One of the best known of these repositories, PubMed, contains already more than 
20 millions citations and these are growing at a once inconceivable rate of almost 2 
papers/minute [12]. 
The value of the information in these repositories of research is huge. Each paper by itself 
constitutes typically a very focused study on one particular biomedical subject that can be 
easily comprehended by other experts in the same field. It is to be expected, however that 
there are also far-reaching correlations between the results of different papers or different 
groups of papers. Uncovering such hidden correlations by hand borders on the impossible 
since, first, the quantity of such papers is by now far beyond the reach of human analysis and, 
secondly, the expertise to understand papers in different areas of research is very hard to find 
in the same individual in today’s era of ever increasing specialization. The potential 
competitive advantage for the first companies to succeed in the task of discovering new 
scientific knowledge this way is considerable, both in speeding up research and in cutting 
costs. This is why machine knowledge discovery, if successful, has the potential to 
revolutionize pharmaceutical research. Not only could one test hypotheses in silico but the 
actual generation of these hypotheses would be in silico, with obvious disruptive advantages.  
 
Discovering biomarkers and phenotypes by text mining? 
To explore if this vision of a new way to generate scientific discovery by machine 
intelligence is feasible, Merck, in collaboration with Thomson Reuters, devised a pilot 
experiment in which the InfoCodex semantic engine was used for the specific and concrete 
task to discover unknown/novel biomarkers and phenotypes for diabetes and/or obesity 
(D&O) by text mining diverse and numerous biomedical research texts [13]. Here I will 
summarize the key points of the methods and the main results.  
The choice fell on biomarkers and phenotypes since these play a paramount role in modern 
medicine. Drugs of the future will be targeted to populations and groups of individuals with 
common biological characteristics predictive of drug efficacy and/or toxicity. This practice is 
called “individualized medicine” or “personalized medicine” [10]. The revealing features are 
called “biomarkers” and “phenotypes”. 
A biomarker is a characteristic that is objectively measured and evaluated as an indicator of 
normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention. In other words, a biomarker is any biological or biochemical entity or signal that 
is predictive, prognostic, or indicative of another entity, in this case, diabetes and/or obesity. 
A phenotype is an anatomical, physiological and behavioral characteristic observed as an 
identifiable structure or functional attribute of an organism. Phenotypes are important 
because phenotype-specific proteins are relevant targets in basic pharmaceutical research. 
Biomarkers and phenotypes constitute one of the “hot threads” of diagnostic and drug 
development in pharmaceutical and biomedical research, with applications in early disease 
identification, identification of potential drug targets, prediction of the response of patients to 
medications, help in accelerating clinical trials and personalized medicine. The biomarker 
market generated $13.6 billion in 2011 and is expected to grow to $25 billion by 2016 [14]. 
The object of the experiment was for the InfoCodex semantic engine to discover 
unknown/novel biomarkers and phenotypes for diabetes and/or obesity (D&O) by text mining 
a diverse and sizable corpus of unstructured, free-text biomedical research documents 
constituted by: 
• PubMed [15] abstracts with titles: 115,273 documents  
• Clinical Trials [16] summaries: 8,960 summaries  
• Internal Merck research documents, about one page in length: 500 documents.  
The output D&O related biomarkers and phenotypes proposed by the machine were then 
compared with Merck internal and external vocabularies/databases including UMLS [17], 
GenBank [18], Gene Ontology [19], OMIM [20], and the Thomson Reuters [21] D&O 
biomarker databases. By design, the experiment was handled strictly as a “blind experiment”: 
no expert input about D&O biomarkers/phenotypes was provided and no feedback from 
preliminary results was used to improve the machine-generated results.  
 
The InfoCodex semantic engine 
InfoCodex is a semantic machine intelligence software designed specifically to analyze very 
large document collections as a whole and thereby unearth associative, implicit and lexically 
unspecified relationships. It does so by unsupervised semantic clustering and matching of 
multi-lingual documents. Its technology is based on a combination of an embedded universal 
knowledge repository (the InfoCodex Linguistic Database, ILD), statistical analysis and 
information theory [22], and self-organizing neural networks (SOM) [23]. 
The ILD contains multi-lingual entries (words/phrases) collected into cross-lingual synonym 
groups (semantic clouds) and systematically linked to a hypernym (taxon) in a universal 7-
level taxonomy. With its almost 4 million classified entries, the ILD corresponds to a very 
large multi-lingual thesaurus (for comparison, the Historical Thesaurus of the English Oxford 
Dictionary, often considered the largest in the world, has 920,000 entries).  
Information theory and statistics [22] are used to establish a 100-dimensional content space 
defined on the ILD that describes the documents in an optimal way. Documents are then 
modeled as 100-dimensional vectors in this optimal semantic space. Information-theoretic 
concepts such as entropy and mutual entropy are used together with the ILD to disambiguate 
the meaning of polysemous words based both on the document-specific context and the 
collection-wide environment.  
Finally, the fully automatic, unsupervised categorization on the optimal semantic space is 
achieved by a proprietary variant of Kohonen’s self-organizing map [23]. In particular, prior 
to starting the unsupervised learning procedure, a coarse group rebalancing technique is used 
to construct a reliable initial guess for the SOM. This is a generalization of coarse mesh 
rebalancing [24] to general iterative procedures, with no reference to spatial equations as in 
the original application to neutron diffusion and general transport theory in finite element 
analysis. This procedure considerably accelerates the iteration process and minimizes the risk 
of getting stuck in a sub-optimal configuration. The SOM creates a thematic landscape 
according to and optimized for the thematic volume of the entire document collection.  
Essentially, the combination of the embedded ILD with the self-organized categorization on 
an automatically determined optimal semantic space correspond to a dynamic ontology, in 
which vertical “is-a” relations are encoded and horizontal relations like “is-correlated-with” 
are determined dynamically depending on content.  
For the comparison of the content of different documents with each other and with queries, a 
similarity measure is used which is composed of the scalar product of the document vectors 
in the 100-dimensional semantic space, the reciprocal Kullback–Leibler distance [25] from 
the main topics, and the weighted score-sum of common synonyms, common hypernyms and 
common nodes on higher taxonomy levels. 
As a final result, a document collection is grouped into a two-dimensional array of neurons 
called an information map. Each neuron corresponds to a semantic class; i.e., documents 
assigned to the same class are semantically similar. The classes are arranged in such a way 
that the thematically similar classes are nearby (Figure 1). 
           
Figure 1 InfoCodex information map. InfoCodex information map obtained for the 
approximately 115,000 documents of the PubMed repository used for the present 
experiment. The size of the dots in the center of each class indicate the number of documents 
assigned to it. 
The described InfoCodex algorithm is able to categorize unstructured information. In a recent 
benchmark, testing the classification of multi-lingual, “noisy” Web pages, InfoCodex reached 
the high clustering accuracy score F1 = 88% [26]. Moreover, it extracts relevant facts not 
only from single documents at hand, but it considers document collections as a whole and 
identifies dispersed and seemingly unrelated facts and relationships like assembling the 
scattered pieces of a puzzle.  
Text mining with InfoCodex in search of new biomarkers/phenotypes  
The text mining procedure involved four steps:  
Generation of reference models: in this step the software had to determine the meaning of 
the concept “biomarker/phenotype for D&O”. Since no input by human experts was allowed 
in the experiment, the only way to do this was by a generic literature search via the 
autonomous InfoCodex spider agents: 224 reference biomarkers/phenotypes were found.  The 
documents containing these reference terms were then clustered by InfoCodex and for each 
group a representative feature vector in the optimal semantic space was established. These 
feature vectors constitute mathematical models on semantic space of what, e.g. “biomarker 
for diabetes” means.  
Determination of the meaning of unknown terms: the ILD contained at the time of the 
experiment about 20,000 genes and proteins (up to around 100’000 presently). Nonetheless it 
was not guaranteed to identify all possibly relevant candidates by a simple database look-up. 
Fortunately, the architecture of InfoCodex allows to infer the meaning of unknown terms by 
combining its “hard-wired” internal knowledge base with the association power of neural 
networks. Some examples of the meanings inferred by InfoCodex are presented in Table 1.  
 
Table 1: InfoCodex computed meanings 
Unknown Term Constructed Hypernym Associated Descriptor 1 
Nn1250 clinical study insuline glargine 
Tolterodine cavity overactive bladder 
Ranibizumab drug macular edema 
Nn5401 clinical study insulin aspart 
Duloxetine antidepressant personal physician 
Endocannabinoid receptor enzyme 
Becaplermin pathology ulcer 
Candesartan cardiovascular disease high blood pressure 
Srt2104 medicine placebo 
Olmesartan cardiovascular medicine amlodipine 
Hctz diuretic drug hydrochlorothiazide 
Eslicarbazepine anti nervous Zebinix 
Zonisamide anti nervous Topiramate Capsules 
Mk0431 antidiabetic sitagliptin 
Ziprasidone tranquilizer major tranquilizer 
Psicofarmcolagia motivation incentive 
Medoxomil cardiovascular medicine amlodipine 
InfoCodex computed meanings of some unknown terms from the experimental PubMed 
collection. 
The meaning of unknown terms is estimated fully automatically; i.e., no human intervention 
was necessary and no context-specific vocabularies had to be provided as in most related 
approaches [27]. The meaning had to be inferred by the semantic engine only based on 
machine intelligence and its internal generic knowledge base, and this automatism is one of 
the main innovations of the presented approach. Some of the estimated hypernyms are 
completely correct: “Hctz” is a diuretic drug and is associated to “hydrochlorothiazide” 
(actually a synonym). Clearly, not all inferred semantic relations are of the same quality. 
Generation of a list of potential biomarkers and phenotypes: most of the reference 
biomarkers and phenotypes found in the literature (see Step 1) were linked to one of the 
following nodes of the ILD: genes, proteins, causal agents, hormones, phenotypes, metabolic 
disorders, diabetes, obesity, symptoms.  
The initial pool of candidates was constructed by considering each term appearing in the 
experimental document base that points to one of the same taxonomy nodes, whether via 
explicit hypernym relations in the ILD or via inferred hypernyms. For each of these 
candidates a group of experimental documents was formed by choosing those documents that 
contain a synonym of the candidate together with synonyms of “diabetes” or “obesity” and 
for each of these groups the InfoCodex feature vector in semantic space was constructed.  
The document group corresponding to one particular initial candidate is compared with the 
previously derived reference models for D&O biomarkers/phenotypes by computing the 
semantic distances to the feature vectors of the reference models. A term qualifies as a final 
candidate for a D&O biomarker or phenotype if the semantic similarity deviation from at 
least one of the corresponding reference clusters is below a certain threshold.  
Establishing confidence levels: not all the biomarker/phenotype candidates established this 
way have the same probability of being relevant. In order to rank the final candidates 
established in Step 3 an empirical score was devised, representing the confidence level of 
each term. This confidence measure is based on the average semantic deviation of the feature 
vector assigned to the candidate from the feature vector of the corresponding reference model 
and additional information-theoretic measures.  
 
Results of the experiment 
The output of the experiment was a list of potential D&O biomarkers/phenotypes as shown in 
Table 2. The candidate terms are listed in column A, with their relation to either diabetes or 
obesity in columns B and C. Columns D and E display the confidence level and the number 
of documents on which the identification of the candidate was based. Finally, the last 
columns contain the detailed IDs to these documents so that they can be retrieved and used by 
human experts for assessment. Note that human expert assessment is actually the only 
meaningful evaluation of the experiment as far as the novelty aspect of the proposed D&O 
biomarkers/phenotypes is concerned.  
    
Table 2: typical output of the experiment 
Row Term 
(A) 
Relationship 
(B) 
Object 
(C) 
Conf% 
(D) 
#Docs 
(E) 
PMIDs 
(F) 
1 glycemic control BiomarkerFor Diabetes 70.3 1122 20110333, 20128112, 20149122, 
2 Insulin PhenoTypeOf Diabetes 68.3 5000 19995096, 20017431, 20043582, 
3 Proinsulin BiomarkerFor Diabetes 67.8 105 16108846, 9405904, 20139232, 
4 TNF alpha inhibitor PhenoTypeOf Diabetes 67.1 245 9506740, 20025835, 20059414, 
5 anhydroglucitol BiomarkerFor Diabetes 67.1 10 20424541, 20709052, 21357907, 
6 linoleic acid BiomarkerFor Diabetes 67.1 61 20861175, 20846914, 15284064, 
7 palmitic acid BiomarkerFor Diabetes 67.1 24 20861175, 20846914, 21437903, 
8 pentosidine BiomarkerFor Diabetes 67.1 13 21447665, 21146883, 17898696, 
9 uric acid BiomarkerFor Obesity 66.8 433 10726195, 19428063, 10904462, 
10 proatrial natriuretic peptide BiomarkerFor Obesity 66.6 4 14769680, 18931036, 17351376, 
11 ALT values BiomarkerFor Diabetes 66.3 2 20880180, 19010326 
12 adrenomedullin BiomarkerFor Diabetes 64.3 7 21075100, 21408188, 20124980, 
13 fructosamin BiomarkerFor Diabetes 64.2 59 20424541, 21054539, 18688079, 
14 TNF alpha inhibitor BiomarkerFor Diabetes 62.1 245 9506740, 20025835, 20059414, 
15 uric acid BiomarkerFor Diabetes 61.8 259 21431449, 20002472, 20413437, 
16 monoclonal antibody BiomarkerFor Obesity 61.7 41 14715842, 21136440, 21042773, 
17 Insulin level QTL PhenoTypeOf Obesity 61.2 1167 16614055, 19393079, 11093286, 
18 stimulant BiomarkerFor Obesity 61.2 646 18407040, 18772043, 10082070, 
19 IL-10 BiomarkerFor Obesity 60.9 120 19798061, 19696761, 20190550, 
20 central obesity PhenoTypeOf Diabetes 59.5 530 16099342, 17141913, 15942464, 
21 lipid BiomarkerFor Obesity 59.5 4279 11596664, 12059988, 12379160, 
22 urine albumin screening BiomarkerFor Diabetes 59.0 95 20886205, 19285607, 20299482, 
23 tyrosine kinase inhibitor BiomarkerFor Obesity 58.8 83 18814184, 9538268, 15235125, 
24 TNF alpha inhibitor BiomarkerFor Obesity 58.0 785 20143002, 20173393, 10227565, 
25 fas BiomarkerFor Obesity 57.7 179 12716789, 17925465, 19301503, 
26 leptin PhenoTypeOf Diabetes 57.6 870 11987032, 17372717, 18414479, 
27 ALT values BiomarkerFor Obesity 57.4 8 16408483, 19010326, 17255837, 
28 lipase BiomarkerFor Obesity 56.8 356 16752181, 17609260, 20512427, 
29 insulin resistance PhenoTypeOf Obesity 55.8 5000 20452774, 20816595, 21114489, 
30 chronic inflammation PhenoTypeOf Diabetes 55.7 154 15643475, 18673007, 18801863, 
The details of the evaluation have been published elsewhere [13] and are beyond the scope of 
the present review. Here I would like to retain the two major conclusions that can be drawn. 
The negative aspect of the experiment is that too much noise was generated as exemplified by 
the obviously implausible or incomplete candidates proposed in Table 3. 
Table 3: implausible and/or incomplete D&O biomarker/phenotype candidates 
Term Relationship Object Target Conf% #Docs 
wenqing BiomarkerFor Obesity Obesity 53.5 29 
proteomic BiomarkerFor Obesity Obesity 40.8 128 
gene expression BiomarkerFor Obesity Obesity 38.9 62 
Mouse model BiomarkerFor Obesity Obesity 19.8 17 
muise BiomarkerFor Obesity Obesity 17.5 20 
athero- BiomarkerFor Obesity Obesity 16.5 6 
shrna BiomarkerFor Obesity Obesity 9.6 4 
inflammation BiomarkerFor Obesity Obesity 8.2 4 
TBD BiomarkerFor Obesity Obesity 7.4 3 
body weight PhenoTypeOf Diabetes MGAT2  1 
cell line BiomarkerFor Diabetes MGAT2  1 
The very positive result, however, is that several candidates of very high quality were 
proposed by the software. These were considered as “needles in the haystack” by the Merck 
experts. While the plausibility of these candidates has been judged very high by human 
experts, a Google search of these terms in conjunction with “diabetes” and/or “obesity” 
produced extremely low hit rates, near or at zero, compared with hundreds of thousands for 
known D&O biomarkers/phenotypes. Unfortunately, these terms are considered as valuable 
proprietary information by Merck and cannot be shown openly, Table 4.  
Table 4: plausible, novel and very valuable D&O biomarker/phenotype candidates 
(hidden since considered valuable proprietary information by Merck)  
Term Relat. Object Target Conf% #Docs 
xxxxxx	   PhenoTypeOf	   Obesity	   Obesity	   7.7	   4	  
xxxxxx	   PhenoTypeOf	   Obesity	   Obesity	   7	   6	  
xxxxxx	   BiomarkerFor	   Obesity	   Obesity	   4.9	   1	  
xxxxxx	   BiomarkerFor	   Obesity	   Obesity	   4.9	   1	  
xxxxxx	   BiomarkerFor	   Obesity	   Obesity	   2.9	   2	  
xxxxxx	   BiomarkerFor	   Obesity	   Obesity	   2.2	   1	  
xxxxxx	   BiomarkerFor	   Obesity	   Obesity	   2.2	   1	  
xxxxxx	   BiomarkerFor	   Obesity	   Obesity	   2.2	   1	  
xxxxxx	   BiomarkerFor	   Diabetes	   Diabetes	   14.5	   1	  
xxxxxx	   BiomarkerFor	   Diabetes	   Diabetes	   2.8	   2	  
  
Compared with recent studies [28-31] aimed at the extraction of drug–gene relations from the 
pharmacogenomic literature, this experiment introduced three novelties. First, while most 
related work is based on high-quality, manually curated knowledge bases such as PharmGKB 
[30] to train the recognition of connections between specific drugs and genes, this 
experiment’s reference/training set (Step 1) was assembled in an ad hoc way by naïve (non-
expert) PubMed search. Second, aside from the generic taxonomy in the ILD, no context-
specific vocabularies (e.g., UMLS) were provided to inform the semantic engine. The 
meaning of unrecognized words had to be inferred by the InfoCodex engine based only on its 
universal internal linguistic database and its association power. Third, the text mining 
algorithms used here do not use rule-based approaches, or analyze co-occurrences sentence 
by sentence, or section by section, but rather they extract knowledge from entire documents 
and their relations with semantically related documents. 
In view of the requirement of no human assistance, the demonstrated capability of 
automatically identifying high quality candidates is extremely encouraging and could prove 
an entirely new way to speed-up pharmaceutical research, with high potential to shorten time-
to-market of novel drugs, or for early recognition of dead ends such as prohibitive side-
effects through targeted extraction of relevant information. 
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